/

MGNX

MacroGenics, Inc.Closed

3.42−0.30 −8.06%USD

NasdaqGS · as of Oct 13, 16:00 ET · 15m delayAfter hours 3.42 0.00%

Open

3.73

Prev close

3.72

Day range

3.423.73

52-week range

1.295.08

Volume

559.12K0.92×

Mkt cap

217.85M

P/E ttm

—

Fwd P/E

-2.33

EPS ttm

-1.70

Div yield

0.00%

Earnings

—

From 52w high

−32.68%

Price Chart

Yahoo Finance · delayed

MGNXOct 12, 2026O 3.72H 3.76L 3.65C 3.72−0.02 (−0.53%)Vol 284.40K

SMA 503.99
SMA 2003.33

1Y change +120.12% since Oct 10, 2025 close538 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

MGNX MacroGenics, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −1.33%
1 month: −7.00%
3 months: −17.33%
6 months: +7.20%
Year to date: +131.06%
1 year: +120.12%

Valuation & ownership

Market cap: 217.85M
Enterprise value: 79.64M
P/E (ttm): —
Forward P/E: -2.33
PEG ratio: —
Price / book: 5.07
Price / sales (ttm): 1.24
EV / EBITDA: -2.48
EPS (ttm): -1.70
EPS (forward): -1.47
Beta (5y monthly): 1.21
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 63.70M
Float: 56.41M
Short % of float: 11.45%
Short ratio (days): 12.63
Held by insiders: 3.49%
Held by institutions: 77.63%
Avg volume (3m): 604.71K
50-day average: 3.99
200-day average: 3.33
52-week change: +120.12%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 45.6
vs 50-day SMA: −6.69%
vs 200-day SMA: +11.75%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 5.97%
Realised vol (20d, ann.): 66.0%
From 52-week high: −26.77%
From 52-week low: +188.37%

ANR

Analyst Consensus

4 analysts

Consensus

—

Mean target

8.00

+133.92% implied

Low 4.00Median 8.50High 11.00

Recommendation trend

Now3 / 4 / 0
1m ago3 / 4 /

DES

About MacroGenics, Inc.

Yahoo Finance profile

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials. It is also developing T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.

Sector: Healthcare
Industry: Biotechnology
Employees: 293
Headquarters: Rockville, MD, United States
Website: macrogenics.com
Officers: Mr. Eric Blasius Risser CEO, President & Director
Mr. James Karrels Senior VP & CFO

SEAS

Seasonality · MGNX

2013–2026 · monthly returns

Strongest month Nov +11.34%Weakest month Mar −7.91%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	13.7	8.7	45.2	6.6	35.1	11.1	-20.1	8.1	-3.3	-11.4			+112.4%
2025	-7.7	-18.0	-48.4	36.6	-21.6	-11.0	28.9	13.5	-5.1	-1.2	-7.8	5.2	−50.5%
2024	48.6	25.5	-17.9	0.4	-72.3	3.9	-11.5	-6.6	-6.3	11.2	-1.9	-9.5	−66.2%
2023	-14.0	5.5	17.7	-3.9	-32.2	14.6	-10.8	-2.3	0.0	12.0	57.3	17.2	+43.4%
2022	-23.1	-24.3	-5.8	-18.8	-51.5	-15.0	6.1	26.8	-12.8	48.0	25.6	4.4	−58.2%
2021	-10.6	22.4	27.3	1.6	-0.5	-16.6	-7.1	-5.4	-11.3	-6.7	-9.9	-8.8	−29.8%
2020	-15.0	-5.2	-33.6	23.7	167.2	45.1	-9.0	13.9	-13.0	-22.9	18.9	-0.9	+110.1%
2019	-7.6	70.5	-10.1	-6.7	9.4	-7.5	-15.2	-0.3	-11.0	-33.4	11.4	14.9	−14.3%
2018	18.8	11.2	0.3	-8.3	-1.4	-9.2	0.0	5.9	-2.0	-23.2	4.6	-26.2	−33.2%
2017	-9.6	14.5	-12.0	16.2	-17.9	-1.4	-5.7	14.5	-2.3	7.1	-2.4	-1.7	−7.0%
2016	-35.0	-20.6	17.3	9.7	24.3	5.6	13.3	-2.5	0.3	-20.8	9.5	-21.2	−34.0%
2015	-9.8	9.3	-9.3	-8.8	13.1	17.4	-1.0	-29.9	-18.7	45.1	11.3	-10.4	−11.7%
2014	45.1	-12.1	-20.5	-28.4	-6.4	16.5	-6.6	5.2	-2.2	1.9	32.7	24.1	+27.9%
2013											-1.7	3.6	+1.8%

INSD

Insider Activity · MGNX

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

81.8K shares

Sells, 6 months

31.1K shares

Net shares

+50.6K

Net change in insider shares

+2.30%

Date	Insider	Transaction	Shares	Value
Oct 5, 2026	Bonvini EzioOfficer	Conversion of Exercise of derivative security at price 2.60 per share.	8K	$20.80K
Aug 18, 2026	Peters Jeffrey StuartGeneral Counsel	Sale at price 4.15 per share.	31.1K	$129.09K
Aug 16, 2026	Bonvini EzioOfficer	Conversion of Exercise of derivative security at price 2.60 per share.	40K	$104.00K
May 17, 2026	Hurwitz EdwardDirector	—	3.8K	—
May 17, 2026	O'Brien Federica FDirector	—	3.8K	—
May 17, 2026	Heiden William KDirector	—	3.8K	—
May 17, 2026	Liu Margaret ADirector	—	3.8K	—
May 17, 2026	Jackson Scott ThomasDirector	—	3.8K	—
May 17, 2026	Siegel Jay Philip M.D.Director	—	3.8K	—
May 17, 2026	Stump David Carter M.D.Director	—	3.8K	—
May 17, 2026	Ferrante Karen Jean M.D.Director	—	3.8K	—
May 17, 2026	Chhabra MeenuDirector	—	3.8K	—
Feb 12, 2026	Karrels JamesChief Financial Officer	—	15K	—
Feb 12, 2026	Spitznagel ThomasOfficer	—	13.3K	—
Feb 12, 2026	Peters Jeffrey StuartGeneral Counsel	—	13.3K	—
Feb 12, 2026	Smith Beth AnnOfficer and Treasurer	—	1.1K	—
Feb 12, 2026	Koenig ScottDirector	—	21.2K	—
Feb 12, 2026	Bonvini EzioOfficer	—	16.7K	—
Feb 12, 2026	Risser Eric BlasiusChief Executive Officer	—	16.7K	—
Feb 5, 2026	Karrels JamesChief Financial Officer	—	16.3K	—

13F

Investors Holding MGNX

latest 13F filings of 29 followed managers

Investors holding MGNX
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$12.2M	0.02%	2.63M	−11%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

MGNX

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

MGNX

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About MacroGenics, Inc.

Seasonality · MGNX

Insider Activity · MGNX

Congress Trades · MGNX

Investors Holding MGNX

Investors Holding MGNX

Congress Trades · MGNX

Insider Activity · MGNX

Seasonality · MGNX

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About MacroGenics, Inc.

Financial Snapshot

Earnings & Dividends

News